Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting

References

• Alving CR. Therapeutic potential of liposomes as drug carriers in leishmaniasis, malaria and vaccines. Targeting of drugs, G Gregoriadis, J Senior, A Trouet. Plenum Press, New York 1982; 285–312
   Google Scholar
• Amselem S, Friedman D. 1997. Solid fat nanoemulsions, US Patent 5,662, 932.
   Google Scholar
• Amselem S, Yogev A, Zawoznik E, Friedman D. Emulsomes, a novel drug delivery technology. Proceedings of the International Symposium on Controlled Release of Bioactive Materials. 1994; vol. 21: 1368–1369
   Google Scholar
• Avis KE. Sterile products. The theory and practice of industrial pharmacy3rd ed., L Lachman, HA Lieberman, JL Kanig. Varghese publishing house, Bombay 1987; 639–677
   Google Scholar
• Bakker-Wouderberg IA, Storm G, Woodle MC. Liposomes in the treatment of infections. J Drug Target 1994; 2: 363–371
   PubMed Web of Science ®Google Scholar
• Berman JD, Ksionski G, Chapman WL, Waits VB, Hanson WL. Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis. Antimicrob Agents Chemother 1992; 36: 1978–1980
   PubMed Web of Science ®Google Scholar
• Bryceson A. Therapy in man. The leishmaniasis in biology and medicine, W Peters, R Killickkendrick. Academic Press Inc. Ltd, London 1987; Vol. II: 847–907
   Google Scholar
• Deneshmed TK, Warnock DW. Clinical pharmacokinetics of antifungal drugs. Clin Pharmacokinet 1983; 8: 17–42
   PubMed Web of Science ®Google Scholar
• Fidler IJ. Targeting of immunomodulator to mononuclear phagocytes for the therapy of cancer. Adv Drug Deliv Rev 1988; 2: 69–106
   Google Scholar
• Fry DW, White JC, Goldman ID. Rapid separation of low molecular weight solutes from liposomes without dilution. Anal Biochem 1978; 90: 809–815
   PubMed Web of Science ®Google Scholar
• Gordon S, Rabinowitz S. Macrophages as targets for drug delivery. Adv Drug Deliv Rev 1989; 4: 27–47
   Google Scholar
• Gupta PK, Huang CT. Albumin microspheres I-physicochemical characteristics. J Microencapsul 1989; 6: 427–462
   PubMed Web of Science ®Google Scholar
• Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: Recent progress and future directions. Clin Infect Dis 1996; 22(Suppl 2)S133–S144
   PubMed Web of Science ®Google Scholar
• Jain S, Vyas SP. Mannosylated niosomes as carrier adjuvant system for topical immunization. J Pharm Pharmacol 2005; 57: 1177–1184
   PubMed Web of Science ®Google Scholar
• Kretschmar M, Amselem S, Zawoznik E, Mosbach K, Dietz A, Hof H, Nichterlein T. Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes). Mycoses 2001; 44: 281–286
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G, Mehta R, Hopffer R, Mills K, Kasi L, Mehta K, Fainstein V, Luna M, Harsh EN, Juliano R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis 1983; 147: 939–945
   PubMed Web of Science ®Google Scholar
• Lowell GH, Kaminski RW, VanCott TC, Slike B, Kersey K, Zawoznik E, Loomis-Price L, Smith G, Redfield RR, Amselem S, Birx DL. Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: Induction of serum, intestinal, vaginal, and lung IgA and IgG. J Infect Dis 1997; 175: 292–301
   PubMed Web of Science ®Google Scholar
• Mehta R, Lopez-Berestein G, Hopffer R, Mills K, Juliano RL. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 1984; 770: 230–234
   PubMed Web of Science ®Google Scholar
• Mullen AB, Carter KC, Baillie AJ. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother 1997; 41: 2089–2092
   PubMed Web of Science ®Google Scholar
• New RRC. Introduction and preparation of liposomes. Liposomes: A practical approach, RRC New. IRL Press, Oxford 1990; 1–104
   Google Scholar
• O'Mullane JE, Artursson P, Tomlinsson E. Biopharmaceutics of microparticulate drug carriers. Biological approaches to the controlled delivery of drugs, RL Juliano. Ann New York Acad Sci. 1987; vol. 507: 120–140
   Google Scholar
• Rex JH, Walsh TJ. Estimating the true cost of amphotericin B. Clin Infect Dis 1999; 29: 1408–1410
   PubMed Web of Science ®Google Scholar
• Sunamoto J, Gato M, Iida T, Hara K, Saito A, Tomonega A. Polymer coated liposomes for drug delivery to target specific organs. Receptor mediated targeting of drugs, G Gregoriadis, J Senior, A Trouet. Plenum Press, New York 1985; 359–371
   Google Scholar
• Takada M, Yuzuriha T, Katayama K, Iwamoto K, Sunamoto J. Increased lung uptake of liposome coated with polysaccharides. Biochim Biophys Acta 1984; 802: 237–244
   PubMed Web of Science ®Google Scholar
• van Etten EW, van den Heuvel-de Groot C, Bakker-Wouderberg IAJM. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidiasis in immunocompetent and leucopenic mice. J Antimicrob Chemother 1993; 32: 723–739
   PubMed Web of Science ®Google Scholar
• van Etten EW, Ottelambillion M, van Vianen W, Tenkate MT, Bakker-Wouderberg IAJM. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother 1995; 35: 509–519
   PubMed Web of Science ®Google Scholar
• van Rooijen NV, Sanders A. Liposome mediated depletion of macrophages: Mechanism of action, preparation of liposomes and applications. J Immunol Method 1994; 174: 83–93
   PubMed Web of Science ®Google Scholar
• Venkatesan N, Vyas SP. Polysaccharide coated liposomes for oral immunization: Development and characterization. Int J Pharm 2000; 203: 169–177
   PubMed Web of Science ®Google Scholar
• Vyas SP. Macrophage targeting and colloidal drug carriers. Advances in lipsomal research, SP Vyas, VK Dixit. CBS Publishers and Distributors, New Delhi 2000; 98–120
   Google Scholar
• Vyas SP, Khar RK. Drug delivery to bone marrow. Targeted and controlled drug delivery, novel carrier systems1st ed., SP Vyas, RK Khar, 2002; 562–585
   Google Scholar
• Vyas SP, Katare YK, Mishra V, Sihorkar V. Ligand directed macrophage targeting of amphotericin B loaded liposomes. Int J Pharm 2000; 210: 1–14
   PubMed Web of Science ®Google Scholar
• Vyas SP, Quraishi S, Gupta S, Jaganathan KS. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm 2005; 296: 12–25
   PubMed Web of Science ®Google Scholar
• Vyas SP, Subhedar R, Jain S. Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. J Pharm Pharmacol 2006; 58: 321–326
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603–618
   PubMed Web of Science ®Google Scholar